Ductal Pancreatic Cancer in Humans and Mice

  1. D.A. TUVESON* and
  2. S.R. HINGORANI
  1. *Department of Medicine, Abramson Family Cancer Research Institute, Abramson Cancer Center at the University of Pennsylvania, Philadelphia, Pennsylvania 19104.
  2. Fred Hutchinson Cancer Research Center, Seattle, Washington 98109.

Abstract

Pancreatic ductal adenocarcinoma (PDA) eludes early detection and resists current therapies, earning its distinction as themost lethal malignancy by organ site in the western world. This dire reality prompted extensive yet generally disappointingefforts to generate transgenic mouse models of this malignancy. Recently, mutant mice that develop pancreatic intraepithelialneoplasms (PanIN), the presumed preinvasive stage of PDA, were produced by conditionally expressing an endogenousoncogenic Kras allele in the developing murine pancreas. Mice with PanIN demonstrated promise in the pursuit of biomarkersof early pancreatic cancer, and, importantly, such mice eventually developed and succumbed to PDA after a long latency,establishing PanINs as true precursors to the invasive disease. Furthermore, the incorporation of conditional mutations in tumorsuppressor alleles known to be altered in human PDA synergized with oncogenic Kras to produce advanced PDA witha short latency, recapitulating central pathophysiological events in human PDA. These models facilitate a variety of biologicaland clinical investigations such as explorations of the cellular origins of PDA and the development of treatment strategiesfor advanced PanIN and PDA. In addition, lessons from modeling PDA may be applicable to other tumor types and illuminategeneral principles of carcinogenesis.

Footnotes

| Table of Contents